Soleno Therapeutics (SLNO) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Soleno Therapeutics is set to release its Q2 2025 earnings on August 6th, with analysts predicting a loss of ($0.85) per share and revenue of $3.91 million.
• After reaching a 52-week high of $90.32, the stock recently opened at $83.97 and has seen a 1.5% decline in value.
• Insider trading reports indicate a significant sale, with Patricia C. Hirano selling 3,830 shares, resulting in a 22.48% reduction in their ownership of Soleno's stock.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results after the market closes on Wednesday, August 6th. Analysts expect Soleno Therapeutics to post earnings of ($0.85) per share and revenue of $3.91 million for the quarter.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.14) by $0.19. On average, analysts expect Soleno Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Soleno Therapeutics Trading Down 0.5%

NASDAQ SLNO traded down $0.47 during trading hours on Friday, hitting $86.00. 1,036,881 shares of the company's stock were exchanged, compared to its average volume of 1,060,843. The firm has a market capitalization of $4.33 billion, a P/E ratio of -18.61 and a beta of -2.63. Soleno Therapeutics has a 12-month low of $41.50 and a 12-month high of $90.32. The company has a debt-to-equity ratio of 0.21, a quick ratio of 19.64 and a current ratio of 19.64. The business's 50 day moving average is $81.87 and its 200-day moving average is $66.60.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on SLNO shares. Wall Street Zen upgraded Soleno Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Guggenheim boosted their price target on Soleno Therapeutics from $81.00 to $97.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Soleno Therapeutics in a research note on Tuesday, April 15th. TD Cowen assumed coverage on Soleno Therapeutics in a research note on Monday, June 23rd. They issued a "buy" rating and a $110.00 price target for the company. Finally, Piper Sandler increased their target price on Soleno Therapeutics from $93.00 to $145.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Soleno Therapeutics has a consensus rating of "Buy" and an average price target of $108.70.

Insider Buying and Selling at Soleno Therapeutics

In other news, insider Patricia C. Hirano sold 3,830 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $82.76, for a total transaction of $316,970.80. Following the completion of the transaction, the insider directly owned 13,206 shares in the company, valued at approximately $1,092,928.56. The trade was a 22.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 6.40% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SLNO. Goldman Sachs Group Inc. increased its stake in shares of Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company's stock valued at $45,236,000 after acquiring an additional 213,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Soleno Therapeutics by 48.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company's stock valued at $2,909,000 after purchasing an additional 13,211 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock worth $1,242,000 after buying an additional 189 shares in the last quarter. 97.42% of the stock is owned by institutional investors and hedge funds.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.